HQP1351
Showing 1 - 8 of 8
Prophylactic HQP1351 Therapy, Third Generation TKI Trial in Guanzhou (HQP1351( Olverembatinib dimesylate))
Withdrawn
- Prophylactic HQP1351 Therapy
- Third Generation TKI
- HQP1351( Olverembatinib dimesylate)
-
Guanzhou, ChinaDepartment of Hematology, Nanfang Hospital, Southern Medical Uni
Jan 16, 2023
Chronic Myeloid Leukemia in Myeloid Blast Crisis, Chronic Myeloid Leukaemia Transformation, Chronic Myeloid Leukemia -
Recruiting
- Chronic Myeloid Leukemia in Myeloid Blast Crisis
- +3 more
- based decitabine and olverembatinib（HQP1351)chemotherapy
-
Guanzhou, ChinaDepartment of Hematology, Nanfang Hospital, Southern Medical Uni
Dec 6, 2022
Chronic Myeloid Leukemia (CML) Trial in Nanjing ([14C] HQP1351)
Completed
- Chronic Myeloid Leukemia (CML)
- [14C] HQP1351
-
Nanjing, ChinaThe First Affiliated Hospital with Nanjing Medical University
Sep 7, 2021
Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase, Tyrosine Kinase Inhibitors Trial in Shenzhen (olverembatinib)
Recruiting
- Olverembatinib
- +2 more
-
Shenzhen, Guangdong, ChinaShenzhen Second People's Hospital
Jul 26, 2022
Chronic Myeloid Leukemia, Chronic Phase Trial in Beijing (HQP1351)
Completed
- Chronic Myeloid Leukemia, Chronic Phase
- HQP1351
-
Beijing, Beijing, ChinaPeking University People's Hospital
Jan 19, 2020
Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia Trial in
Not yet recruiting
- Lymphoblastic Leukemia, Acute, Childhood
- +3 more
- Olverembatinib, APG-2575, Dexamethasone
-
Hefei, Anhui, China
- +3 more
Aug 8, 2022